EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse

Camilla Poulsen, Kristian Juul Sandahl, Lene Karlsson, Jonas Abrahamsson iD, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Linda Fogelstrand, Jose Maria Fernandez Navarro, Bianca F Goemans, Kirsi Jahnukainen, Gertjan Kaspers iD und 10 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/1545-5017.70513 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Camilla Poulsen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Neoplasm Recurrence, Local, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Danish Childhood Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management.

Methods

We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first relapse after initial treatment according to the NOPHO‐DBH AML 2012 protocol.

Results

The 4‐year overall survival (OS 4y ) was 44% (95% confidence interval [CI]: 36%–51%). OS 4y was 61% (CI: 51%–69%) in 133/188 patients who received stem cell transplantation (SCT) after reinduction therapy. Nineteen patients treated at the time of molecular relapse showed an excellent OS 4y of 84% (CI: 58%–95%). Patients with hematological relapse and MRD

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansChildFemaleChild, PreschoolFlow CytometryMaleAdolescentPrognosisInfantSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

acute myeloid leukemiameasurable residual diseasepediatricsrelapse

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Pediatrics, Institution for Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Pediatric Hemato-Oncology, Rambam Health Care Campus, Haifa, Israel.
  • Department of Pediatrics and Adolescent Medicine, Hong Kong Children's Hospital and The University of Hong Kong, Hong Kong, China.
  • Hong Kong Pediatric Hematology and Oncology Study Group (HKPHOSG), Hong Kong, China.
  • Department of Pediatric Hematology-Oncology, Ghent University Hospital, Gent, Belgium.

ORCID-Profile: Jonas Abrahamsson, Gertjan Kaspers, Cornelis Jan Pronk, Kristian Løvvik Juul-Dam

Förderung

  • The Danish Childhood Cancer Foundation

Zitieren

APA

Poulsen, C., Sandahl, K. J., Karlsson, L., Abrahamsson, J., Arad-Cohen, N., Cheuk, D., De Moerloose, B., Fogelstrand, L., Navarro, J. M. F., Goemans, B. F., Jahnukainen, K., Kaspers, G., Kovalova, Z., Munthe-Kaas, M. C., Norén-Nyström, U., Palle, J., Pasauliene, R., Pronk, C. J., Saks, K., …, & Juul-Dam, K. L. (2026). Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse. Pediatric Blood & Cancer. https://doi.org/10.1002/1545-5017.70513

Vancouver

Poulsen C, Sandahl KJ, Karlsson L, Abrahamsson J, Arad-Cohen N, Cheuk D, et al. Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse. Pediatric Blood & Cancer. 2026. doi:10.1002/1545-5017.70513

BibTeX
@article{Poulsen2026,
  author = {Poulsen, Camilla and Sandahl, Kristian Juul and Karlsson, Lene and Abrahamsson, Jonas and Arad-Cohen, Nira and Cheuk, Daniel and De Moerloose, Barbara and Fogelstrand, Linda and Navarro, Jose Maria Fernandez and Goemans, Bianca F and Jahnukainen, Kirsi and Kaspers, Gertjan and Kovalova, Zhanna and Munthe-Kaas, Monica Cheng and Norén-Nyström, Ulrika and Palle, Josefine and Pasauliene, Ramune and Pronk, Cornelis Jan and Saks, Kadri and Tierens, Anne and Hasle, Henrik and Juul-Dam, Kristian Løvvik},
  title = {Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/1545-5017.70513}
}
Kostenlos starten →